KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $2.30 $2.95 Friday, 26th Apr 2024 CLLS stock ended at $2.51. This is 0.627% more than the trading day before Thursday, 25th Apr 2024. During the day the stock fluctuated 6.62% from a day low at $2.35 to a day high of $2.51.
90 days $2.30 $3.13
52 weeks $0.96 $3.77

Historical Cellectis S.A. prices

Date Open High Low Close Volume
Mar 07, 2016 $25.79 $26.53 $25.50 $26.49 176 200
Mar 04, 2016 $30.37 $30.37 $25.51 $26.29 193 600
Mar 03, 2016 $25.42 $26.44 $24.82 $26.41 176 300
Mar 02, 2016 $24.63 $25.85 $24.51 $25.42 273 600
Mar 01, 2016 $23.73 $25.20 $23.53 $25.14 281 800
Feb 29, 2016 $23.20 $24.46 $23.05 $23.81 317 700
Feb 26, 2016 $22.02 $23.03 $21.57 $22.89 276 100
Feb 25, 2016 $21.31 $22.08 $21.25 $21.50 43 000
Feb 24, 2016 $20.90 $21.52 $20.31 $21.32 82 800
Feb 23, 2016 $21.85 $21.90 $21.10 $21.28 62 500
Feb 22, 2016 $22.36 $22.48 $21.83 $22.17 138 000
Feb 19, 2016 $22.02 $22.18 $21.43 $22.06 109 400
Feb 18, 2016 $23.93 $23.93 $21.68 $21.96 295 400
Feb 17, 2016 $22.00 $24.23 $21.61 $23.32 367 000
Feb 16, 2016 $22.95 $22.95 $20.89 $21.25 363 900
Feb 12, 2016 $19.50 $19.52 $18.86 $19.45 92 800
Feb 11, 2016 $18.83 $19.49 $18.61 $19.30 65 700
Feb 10, 2016 $19.51 $20.04 $19.14 $19.38 78 000
Feb 09, 2016 $18.13 $19.13 $18.00 $18.77 133 100
Feb 08, 2016 $19.71 $19.71 $18.79 $19.45 93 800
Feb 05, 2016 $21.32 $21.32 $20.12 $20.41 101 600
Feb 04, 2016 $20.19 $21.61 $19.80 $21.50 161 700
Feb 03, 2016 $20.95 $20.99 $19.83 $20.27 346 300
Feb 02, 2016 $22.35 $22.35 $20.66 $20.91 180 300
Feb 01, 2016 $22.70 $23.01 $21.52 $22.08 218 900
Click to get the best stock tips daily for free!

About Cellectis S.A.

Cellectis S.A. Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALL... CLLS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT